Fresenius Group Overview

Outlook

Group Outlook 2020

In 2020, we expect to increase Group sales1 by 3% to 6% in constant currency. Group net income2,3 is expected to develop in a range of -4% to +1%. Fresenius recognizes the increasing COVID-19 case numbers, and the associated various containment measures being enacted in many of the Company’s relevant markets. Thus, the Group’s FY/20 guidance assumes no containment measures that have a significant and direct impact on the health care sector that are not appropriately compensated.

  Targets 20204 Fiscal year 20195
Fresenius Group
Sales growth (in constant currency) + 3% to + 6% € 35,409 million
Net income2 growth
(in constant currency)
- 4% to + 1% € 1,879 million
Fresenius Medical Care
Sales growth (in constant currency) Mid-to-high
single-digit
%-range
€ 17,477 million
Net income6 growth (in constant currency) Mid-to-high
single-digit
%-range
€ 1,236 million
Fresenius Kabi
Sales growth (organic) + 2% to + 5% € 6,919 million
EBIT growth (in constant currency) - 6% to - 3% € 1,205 million
Fresenius Helios
Sales growth (organic) + 1% to + 4% € 9,234 million
EBIT growth broadly stable € 1,025 million
Fresenius Vamed
Sales growth (organic) ~ - 10% € 2,206 million
EBIT growth positive EBIT € 134 million

 

  • 1 Base 2019: € 35,409 million, including IFRS 16, including NxStage operations
  • 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
  • 3 Base 2019: € 1,879 million, before special items, including IFRS 16, including NxStage operations
  • 4 Before special items, including estimated COVID-19 effects
  • 5 Before special items, including IFRS 16, including NxStage operations
  • 6 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
  •  
  • As of October 29, 2020